Global Testosterone Replacement Therapy (TRT) Market to Exceed $5.0 Billion by 2017, According to New Report by Global Industry Analysts, Inc.
Topical gels were first introduced in 2000 and currently represent the predominantly used therapy, as stated by the new market research report on Testosterone Replacement Therapy (TRT). Apart from Androgel and Testim, the two dominant gel brands in the market, other gels in the market include Tostran and the recently approved Axiron, while Bio-T-Gel, and other gels are currently at different stages of clinical trials. The United States dominates the global TRT market, with gels being the predominant segment. Though the use of injections has declined significantly in the US subsequent to the introduction of gels, but they retain significant share in the European market.
Testosterone Therapy
Global TRT market is highly consolidated, with the three top brands, Androgel, Testim and Androderm, accounting for a major share of the global value market. Apart from biotechnology companies and specialty pharmaceutical firms, the TRT market is also witnessing the foray of large multinational pharmaceutical companies such as Eli Lilly, Bayer Schering, GlaxoSmithKline Plc., and Abbott Laboratories. Other players in the TRT market include Acrux Limited, Auxilium Pharmaceuticals, Inc., Endo Pharmaceuticals, Inc., ProStrakan Group PLC, Slate Pharmaceuticals, Inc., and Watson Pharmaceuticals Inc.
The research report titled “Testosterone Replacement Therapy (TRT): A Global Strategic Business Report” announced by Global Industry Analysts, Inc., provides a comprehensive review of market trends, issues, drivers, company profiles, mergers, acquisitions and other strategic industry activities. The report provides market estimates and projections in US$ Million for Testosterone Replacement Therapy by three product segments: Gels, Patches, and Others (including injectables, oral, pellets, and buccals) for major geographic markets including the US, Canada, Europe, Asia-Pacific, Latin America and the Rest of World.
About Global Industry Analysts, Inc. Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world’s largest market research publishers. The company employs over 800 people worldwide and publishes more than 1200 full-scale research reports each year. Additionally, the company also offers thousands of smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.
Read it all at www.sfgate.com
Testosterone Therapy
Global Testosterone Replacement Therapy (TRT … GIA announces the release of a comprehensive global report on Testosterone Replacement Therapy – blogReaction.
New research claims Testosterone therapy may be safe for men with …
The men received testosterone therapy for an average of two and a half years, and had periodic prostate biopsies. None of their cancers progressed or spread to other organs. One subject whose score had increased to 7 from 6 had his …
Testosterone therapy for prostate cancer needs reevaluation: New …
The long-standing prohibition against testosterone therapy in men with untreated or low-risk prostate cancer merits reevaluation, according to a new study published in The Journal of Urology. For many decades …
Buying Testosterone Over The Counter Testosterone Replacement Therapy
… the gym with minimal benefit, aching joints of the shoulders, hips, knees, and feet, mental fog, depression, difficulty focusing, decreased concentration and poor memory, then you are a suitable candidate for Testosterone Therapy. …
the attachments to this post:
Testosterone_Therapy-6815.jpg
Testosterone_Therapy-6815.jpg
